Lowering cholesterol to protect heart health in Type 1 diabetes
Official title: Cholesterol reduction and cardiovascular risk in Type 1 diabetes
Funded at New York University School of Medicine · NIH-11173604 · Data updated 2026-11-12
People with Type 1 diabetes will take strong cholesterol‑lowering medicines for one month to find out if they reduce blood inflammation and help damaged arteries heal.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 5, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $844,283 |
| NIH project number | 5R01HL164949-04 |
| Project ID | NIH-11173604 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Type 1 diabetes who can take cholesterol-lowering medicines and are willing to attend study visits and blood testing at NYU Langone or Mount Sinai.
✕Less likely to help
People without Type 1 diabetes, children, or anyone who cannot tolerate PCSK9 inhibitors, high-dose statins, or ezetimibe are unlikely to benefit from participating.
What this research studies
You would be treated at NYU Langone or Mount Sinai with powerful cholesterol-lowering drugs, including a PCSK9 inhibitor plus either a high-dose statin (atorvastatin 80 mg) or ezetimibe, for four weeks. Each person acts as their own comparison by measuring markers before and after treatment. Doctors will take blood tests to measure platelets, white blood cells, and circulating inflammatory factors to see how the body’s repair processes change. The goal is to identify biological pathways related to poor artery repair in people with Type 1 diabetes that could be targeted by future treatments.
Why it matters
Potential benefit: If successful, this could point to new ways to improve artery repair and lower heart attack and stroke risk in people with Type 1 diabetes.
How similar studies have gone: Lowering LDL cholesterol reduces cardiovascular events in the general population, but applying PCSK9 therapy and studying immune and repair responses specifically in Type 1 diabetes is relatively novel.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Goldberg, Ira J — New York University School of Medicine
- Study coordinator: Goldberg, Ira J
Related research
Other NIH-funded projects on the same topics.
-
Circadian rhythms and sleep for better blood sugar and heart health in adults with type 1 diabetes
A study tests whether improving sleep duration and regularity can help adults with type 1 diabetes control blood sugar and lower heart-disease risk.
-
Cholesterol lowering and heart risk in adults with type 1 diabetes
This project tests how heart-healthy cholesterol reduction affects blood vessels in adults with type 1 diabetes to help prevent heart disease.
-
Sleep timing, blood sugar control, and heart health in adults with type 1 diabetes
This project looks at whether making sleep longer and more regular helps adults with type 1 diabetes keep blood sugar steadier and reduce heart disease risk.
-
How sleep affects blood sugar control and heart health in adults with type 1 diabetes
This study is looking at how getting better sleep can help adults with type 1 diabetes manage their blood sugar levels and stay healthier, so if you struggle with sleep and diabetes, this research might be for you!
-
Investigating cholesterol reduction and heart disease risk in Type 1 diabetes
This study is looking at how lowering LDL cholesterol can help heart health in people with Type 1 diabetes, and it’s inviting participants from different communities in New York City to try out cholesterol-lowering treatments for four weeks to see how their bodies respond.
-
Technological and Educational Approaches to Restore Hypoglycemia Awareness in Type 1 Diabetes
A two-arm study in adults with type 1 diabetes tests whether high-tech glucose control plus education or targeted training can help people regain awareness of low blood sugar.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.